25.06.2019
Board Meeting No 5 2019
Board Meeting No 5. June 25th 2019
25.06.2019
Notice and Protocol Annual Meeting 2019
June 25th 2019 Notice of Annual Meeting June 25th 2019. The Annual Meeting 2019 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
25.06.2019
Annual Report 2018
Regenics post a positive 2018 result of 1.72 mill NOK. 
13.06.2019
3D-bioprinting - ERA-NET BlueBio Joint Transnational Call 2019
BlueBio Joint Transnational Call 2019
08.05.2019
Board Meeting No 4 2019
Board Meeting No 4 2019, May 8th 2019
18.04.2019
Paragon Nordic AB - Collaboration
Paragon Nordic AB - Collaboration
13.03.2019
Patent annuities paid 2019
Regenics patents due for annuity/fee payments in May 2019 have been paid and continued by our patent legal consultant.
06.03.2019
Filing of additional Hong Kong patent application
The Patents registry of the Hong Kong Intellectual Property Department has verified receipt of Hong Kong Patent Application No. 16104205.5 from Regenics on January 25th 2019. The Hong Kong patent...
06.03.2019
Filing of new US provisional patent application
Filing of new US provisional patent application
28.02.2019
Board Meeting No 2 2019
March 5th 2019. 
23.01.2019
Regenics Board Meeting No 1 2019
January 23rd 2019.  
23.01.2019
Protocol Extraordinary Annual Meeting January 23rd 2019
January 23rd 2019 Protocoll of Extraordinary Annual Meeting January 23rd 2019. The Extraordinary Annual Meeting 2019 took place in the Companys office, Karvesvingen. 2, Oslo
18.12.2018
New EPO Patent granted 2018
New EPO patent
10.12.2018
Eqology AS launch Collagen Booster Serum
 An important commercial milestone has been reached for Regenics December 10th with the launch of the ground breaking EQ Collagen Boosting Serum from the Norwegian Direct Selling Company Eqology AS.  
30.11.2018
Protocol from Extraordinary Annual Meeting September 26th 2018
September 26th 2018 Protocol of Extraordinary Annual Meeting September 26th 2018. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
29.11.2018
Notification of grant:Divisional EPO patent
Notification of grant: Divisional EPO patent

<<  <   Page 2 of 8   >  >>

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.